Evotec SE (LTS:0IRF) EV-to-Revenue : 3.06 (As of May. 02, 2024)

View and export this data going back to 2009. Start your Free Trial

What is Evotec SE EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Evotec SE's enterprise value is €1,735.1 Mil. Evotec SE's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €567.9 Mil. Therefore, Evotec SE's EV-to-Revenue for today is 3.06.

The historical rank and industry rank for Evotec SE's EV-to-Revenue or its related term are showing as below:

LTS:0IRF' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.03 Med: 5.58 Max: 14.61
Current: 3.06

During the past 13 years, the highest EV-to-Revenue of Evotec SE was 14.61. The lowest was 2.03. And the median was 5.58.

LTS:0IRF's EV-to-Revenue is ranked worse than
61.09% of 1023 companies
in the Drug Manufacturers industry
Industry Median: 2.36 vs LTS:0IRF: 3.06

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-02), Evotec SE's stock price is €9.7175. Evotec SE's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €3.21. Therefore, Evotec SE's PS Ratio for today is 3.03.

Evotec SE EV-to-Revenue Historical Data

The historical data trend for Evotec SE's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE EV-to-Revenue Chart

Evotec SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

8.10

9.89

11.59

3.30

4.84

Evotec SE Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															3.91	3.30	5.16	5.46	4.84

Competitive Comparison of Evotec SE's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evotec SE's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evotec SE's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Evotec SE's EV-to-Revenue falls into.

Evotec SE EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Evotec SE's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	1735.126	/	567.87
	=	3.06

Evotec SE's current Enterprise Value is €1,735.1 Mil.
Evotec SE's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €567.9 Mil.

Evotec SE (LTS:0IRF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Evotec SE's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	9.7175	/	3.209
	=	3.03

Evotec SE's share price for today is €9.7175.
Evotec SE's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.21.

Evotec SE EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Evotec SE's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Evotec SE (LTS:0IRF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (LTS:0IRF) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

EVO:USA EVOTF:USA 1EVT:Italy EVTd:UK EVT:Germany EVT:Austria

Address

Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419

Website

https://www.evotec.com

Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally and through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.

Evotec SE (LTS:0IRF) Headlines

No Headlines